NL-OMON29878尚未招募3 期
A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximab
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- Genmab
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •diagnosis of Follicular Lymphoma grade 1* 2 refractory to rituximab in combination with chemotherapy or to rituximab given as maintenance treatment
排除标准
- •The most important exclusion criteria consist of allogenic stem cell transplantation at any time, autologous stem cell transplantation within 6 months prior to Visit 1, more than 1 previous cycle of radio immunotherapy, anticancer therapy or corticosteroid therapy within 4 weeks prior to Visit 1 or known or suspected transformation of the follicular lymphoma to aggressive lymphoma unless new biopsy confirms FL.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximabon-Hodgkin Follicular LymphomaClassification code 10003899EUCTR2006-001433-17-DKGenmab A/S162
进行中（未招募）
不适用
A double-blind, randomized, two-dose-arm, parallel, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximabFollicular LimphomaMedDRA version: 14.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2006-001433-17-ITGLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD161
进行中（未招募）
不适用
A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximabEUCTR2006-001433-17-DEGlaxo SmithKline Research and Development Limited120
进行中（未招募）
不适用
A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab in combination with chemotherapy - HuMax-CD20 in FL patients refractory to rituximabon-Hodgkin Follicular LymphomaMedDRA version: 8.1Level: PTClassification code 10003899Term: B-cell lymphomaEUCTR2006-001433-17-NLGenmab A/S162
进行中（未招募）
不适用
Bioequivalence study with clinical endpoint in the treatment of subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.CTRI/2022/04/042203Amneal EU Limited